Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. GDC-6036) and an PI3K-inhibitor (e.g. inavolisib) and methods of using such combination therapies.
Type:
Application
Filed:
April 4, 2023
Publication date:
October 12, 2023
Applicant:
Genentech, Inc.
Inventors:
Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Zhen SHI, Chunyan SONG, Neekesh Vijay DHARIA, Stephanie Royer JOO
Abstract: The present invention relates to complement C1r subcomponent (C1R) inhibitors for use in treatment of neurological diseases. The invention in particular relates to the use of C1R inhibitors for down-regulation of C1R expression. The invention also relates to nucleic acid molecules, which are complementary to C1R and capable of reducing the level of an C1R mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of neurological diseases.
Type:
Application
Filed:
November 9, 2022
Publication date:
October 12, 2023
Applicant:
Genentech, Inc.
Inventors:
Alexander MUNK, Helene M. GYLLING, Jesse Eric HANSON, Lukasz J. KIELPINSKI
Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
Type:
Grant
Filed:
December 3, 2020
Date of Patent:
October 10, 2023
Assignees:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Cheol Keun Chung, Jie Xu, Hans Iding, Kyle Clagg, Michael Dalziel, Alec Fettes, Francis Gosselin, Ngiap-Kie Lim, Andrew McClory, Haiming Zhang, Paroma Chakravarty, Karthik Nagapudi, Sarah Robinson
Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
Abstract: Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
Type:
Application
Filed:
June 9, 2023
Publication date:
October 5, 2023
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Jennifer Lee Schutzman, Chunyan Song, Kyung Wha Song, Eirini Thanopoulou, Simon Peter Warburton, Anwesha Dey, Stephanie Royer Joo
Abstract: The present disclosure relates to methods and compositions for determining the relative distribution of glucuronidation, iduronidation, and/or galacturonidation of polypeptides, including stereoselective liquid chromatography-mass spectrometry (LC-MS) methods capable of achieving the simultaneous separation and relative quantitation of glucuronidation, iduronidation, and/or galacturonidation of polypeptides.
Abstract: Processes for preparing biheteroaryl compounds are provided, including the biheteroaryl compound 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine. Among other advantages, the processes provide for: the use of solvents that are relatively non-toxic and inexpensive; reduced usage of expensive precious metal catalysts; reaction temperature reduction in certain steps; the use of relatively non-toxic oxidation agents; the use of inexpensive transition metal catalysts; a reduction of molar ratios of certain reactants thereby improving process efficiency while reducing cost and waste; significantly higher reactant concentrations in certain steps; elimination of the need for multiple chromatographic purification steps; elimination of the need for certain extraction steps using organic solvent; and provide for higher yield and improved purity.
Type:
Application
Filed:
March 31, 2023
Publication date:
October 5, 2023
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Fabienne HOFFMANN-EMERY, Manuel KONRATH, Christian LAUTZ, Katrin Monika NIEDERMANN, Jonathan Ugo ORCEL, Diane Elizabeth CARRERA
Abstract: The present invention relates to complement component 4 (C4) inhibitors for use in treatment of a neurological disease. The invention in particular relates to the use of C4 inhibitors for down-regulation of C4 expression. The invention also relates to nucleic acid molecules, which are complementary to C4A and/or C4B and capable of reducing the level of an C4A and/or C4B mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a neurological disease.
Type:
Application
Filed:
November 9, 2022
Publication date:
October 5, 2023
Applicant:
Genentech, Inc.
Inventors:
Alexander MUNK, Helene M. GYLLING, Jesse Eric HANSON, Lukasz J. KIELPINSKI
Abstract: Assays to analyze quality and quantity attributes of fixed dose combinations are provided. In particular, assays for fixed dose combinations of two anti-HER2 antibodies, and for subcutaneous formulations comprising pertuzumab and trastuzumab are described herein.
Type:
Application
Filed:
January 11, 2023
Publication date:
October 5, 2023
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Cécile AVENAL, Nadine HOLZMANN, Michael NOAK, Tania RUCHTY, Gabriele Maria SCHAEFER, Franziska ZAEHRINGER
Abstract: A syringe (18) has a longitudinal body (28) with an interior (228) in which a pharmaceutical substance is arranged, a needle connected to one longitudinal end of the body (228) and a rigid needle shield (38) encasing the needle. The rigid needle shield (38) is essentially water vapour tight. The syringe (18) according to the invention allows for preventing needle clogging and, thus, proper provision of pharmaceuticals, particularly by subcutaneous, intramuscular or ocular injection.
Type:
Grant
Filed:
February 18, 2022
Date of Patent:
October 3, 2023
Assignees:
HOFFMANN-LA ROCHE INC., GENENTECH, INC.
Inventors:
Frank Bamberg, Heather L. Flores, Robert Müller, Elisabeth Schaible, Edward Schwarb, Lionel Vedrine, Kewei Yang, Mathieu Rigollet, Pierre Goldbach, Baboo Dushyantsingh Goordyal, Ivy Lin, Florian Wildenhahn
Abstract: The present disclosure relates to techniques for continuous integration and continuous deployment of source code on a digital health platform. Particularly, aspects are directed to receiving source code from a software development system (the source code being validated in accordance with a first QMS), generating a profile for the source code, classifying the source code into a class of code based on the profile, retrieving a second QMS associated with the class of code, validating the source code in accordance with the second QMS, upon validation of the source code, executing a build process to generate a executable program from the source code, encapsulating the executable program in a container, and deploying the container on one or more nodes of a software platform. The first QMS is adapted from the perspective of the software development system; whereas the second QMS is adapted from the perspective of the software platform.
Abstract: The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.
Type:
Grant
Filed:
March 14, 2017
Date of Patent:
September 26, 2023
Assignees:
Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
Abstract: The present application relates to systems and methods for assaying presence of large molecule analytes, such as proteins, e.g., antibodies, antigens, receptors, and the like, using a targeted two-dimensional liquid chromatography, tandem mass spectrometry (2D-LC-MS/MS) system, optionally combined with affinity capture. In some aspects, the system is partially or fully automated. In some aspects, the system may allow detection of protein biomarkers (e.g., antibodies or antigens) from clinical or nonclinical biological tissue or fluid samples in the pg/mL to ng/mL range.
Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
September 19, 2023
Assignee:
Genentech, Inc.
Inventors:
Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Tiffany Wong, Jia Wu, Hongkang Xi, Jack Bevers, III, Hiu Nam Chan, Laetitia Comps-Agrar, Racquel Corpuz
Abstract: Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.
Type:
Grant
Filed:
August 15, 2019
Date of Patent:
September 19, 2023
Assignee:
Genentech, Inc.
Inventors:
Aijun Lu, Sushant Malhotra, Alan G. Olivero, Cheng Shao, Yamin Zhang, Steven Do
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
Type:
Grant
Filed:
October 20, 2020
Date of Patent:
September 19, 2023
Assignee:
Genentech, Inc.
Inventors:
Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Type:
Application
Filed:
January 26, 2023
Publication date:
September 14, 2023
Applicant:
Genentech, Inc.
Inventors:
Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG